Johnson & Johnson Poised For A Muted Q2?

Johnson & Johnson stock (NYSE: JNJ) will report its Q2 2023 results on Thursday, July 20. We expect the company’s revenues to come in at $24.6 billion, marginally below the consensus estimate of $24.7 billion. This would mark year-over-year growth of about 2%. Earnings will likely come in at about…#johnsonjohnson #jnj #darzalexerleada #remicade #medtech #abiomed #johnsonjohnsons #consumerhealthcare #johnsonjohnsonpeers #peercomparisons

Source: Reuters: Health - July 14, 2023 Category: Consumer Health News Source Type: news